Long
MYND ANALYTICS STOCK PRICE COULD DOUBLE
INVESTORS ARE REWARDED FOR LOYALTY WITH MAJOR STOCK MOVES ON MERGER CLARITY
Yutaka Niihara, MD, MPH, CEO and Chairman of Emmaus, stated, "We are very grateful for this opportunity to merge with MYnd Analytics. The anticipated listing on Nasdaq via the merger with MYnd Analytics is an important step to maximize value for shareholders. We look forward to sharing with the public markets our progress on the market acceptance of Endari, which is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years and older. Endari addresses a $3 billion global market. In addition to the treatment of sickle cell disease, we believe our platform technology has the potential to address other major clinical indications such as diverticulosis."
Robin Smith, Chairman of MYnd Analytics, commented, "We are pleased with the progress of the merger and spin-off transaction, which remains on track to close before the end of this month, subject to approval of shareholders. We believe this transaction will drive significant value for all shareholders, and we will provide further updates following the respective shareholder meetings."
AVERAGE ANALYSTS PRICE TARGET $4
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
MYnd Analytics, Inc. operates as a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. It provides objective clinical decision support to mental healthcare providers for the personalized treatment of behavioural disorders, includes depression, anxiety, bipolar disorder, post-traumatic stress disorder, and other non-psychotic disorders. The company was founded by Leonard J. Brandt and Brain McDonald on March 20, 1987 and is headquartered in Aliso Viejo, CA.
Yutaka Niihara, MD, MPH, CEO and Chairman of Emmaus, stated, "We are very grateful for this opportunity to merge with MYnd Analytics. The anticipated listing on Nasdaq via the merger with MYnd Analytics is an important step to maximize value for shareholders. We look forward to sharing with the public markets our progress on the market acceptance of Endari, which is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years and older. Endari addresses a $3 billion global market. In addition to the treatment of sickle cell disease, we believe our platform technology has the potential to address other major clinical indications such as diverticulosis."
Robin Smith, Chairman of MYnd Analytics, commented, "We are pleased with the progress of the merger and spin-off transaction, which remains on track to close before the end of this month, subject to approval of shareholders. We believe this transaction will drive significant value for all shareholders, and we will provide further updates following the respective shareholder meetings."
AVERAGE ANALYSTS PRICE TARGET $4
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
MYnd Analytics, Inc. operates as a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. It provides objective clinical decision support to mental healthcare providers for the personalized treatment of behavioural disorders, includes depression, anxiety, bipolar disorder, post-traumatic stress disorder, and other non-psychotic disorders. The company was founded by Leonard J. Brandt and Brain McDonald on March 20, 1987 and is headquartered in Aliso Viejo, CA.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.